NRXP insider filings
NRX Pharmaceuticals, Inc. — 47 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-04. Screen NRXP transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| ABRAMS MICHAEL S — Chief Financial Officer | 1 | — | — | 1 |
| Javitt Jonathan C — CEO and Chairman, Director | 1 | — | — | 1 |
Recent insider filings — NRX Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | Javitt Jonathan C — CEO and Chairman, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-11-04 | 4 | ABRAMS MICHAEL S — Chief Financial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Casper Joseph Michael — Chief Operating Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-09-10 | 4 | McBride Dennis — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-09-10 | 4 | Flynn Patrick John — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-09-10 | 4 | Hurvitz Chaim — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-09-10 | 4 | Javitt Jonathan C — Chairman and Chief Scientist, Director, 10% owner | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | ABRAMS MICHAEL S — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Javitt Jonathan C — Chairman and Chief Scientist, Director, 10% owner | Purchase (P): 40,000 @ $1.17 | EDGAR |
| 2023-09-11 | 4 | Gorovitz Aaron — Director | Purchase (P): 35,000 @ $0.32 | EDGAR |
| 2023-09-11 | 4 | Hurvitz Chaim — Director | Purchase (P): 70,000 @ $0.29 | EDGAR |
| 2023-08-24 | 4 | Javitt Jonathan C — Chief Scientist, Director, 10% owner | Purchase (P): 100,000 @ $0.33 | EDGAR |
| 2023-08-23 | 4 | Javitt Jonathan C — Chief Scientist, Director, 10% owner | Purchase (P): 200,000 @ $0.32 | EDGAR |
| 2022-12-19 | 4 | Willard Stephen H — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 50,000 @ $1.17 | EDGAR |
| 2022-12-19 | 4 | VAN VOORHEES SETH — CHIEF FINANCIAL OFFICER | Purchase (P): 30,000 @ $1.10 | EDGAR |
| 2022-12-19 | 4/A | VAN VOORHEES SETH — CHIEF FINANCIAL OFFICER | Purchase (P): 8,716 @ $1.12 · Purchase (P): 600 @ $1.10 · Purchase (P): 7,021 @ $1.11 | EDGAR |
| 2022-12-09 | 4 | Javitt Jonathan C — Director, 10% owner | Sale (S): 400,000 @ $1 | EDGAR |
| 2022-12-01 | 4 | Javitt Daniel C. — 10% owner | Sale (S): 13,730 @ $1.50 · Sale (S): 8,441 @ $1.50 | EDGAR |
| 2022-11-29 | 4 | Flynn Patrick John — Director | Purchase (P): 2,500 @ $1.25 · Purchase (P): 2,500 @ $1.25 · Purchase (P): 2,500 @ $1.25 · Purchase (P): 2,500 @ $1.24 · Purchase (P): 1,750 @ $1.25 | EDGAR |
| 2022-11-28 | 4 | VAN VOORHEES SETH — CHIEF FINANCIAL OFFICER | Purchase (P): 8,716 @ $1.12 · Purchase (P): 600 @ $1.10 · Purchase (P): 7,021 @ $1.11 | EDGAR |
| 2022-11-23 | 4/A | Hurvitz Chaim — Director | Purchase (P): 287,812 @ $0.99 · Purchase (P): 171,780 @ $1.08 · Purchase (P): 40,408 @ $1.10 | EDGAR |
| 2022-11-22 | 4 | Gorovitz Aaron — Director | Grant/award (A): 162,660 (derivative) | EDGAR |
| 2022-11-22 | 4 | Glied Sharon — Director | Grant/award (A): 162,660 (derivative) | EDGAR |
| 2022-11-22 | 4 | Flynn Patrick John — Director | Grant/award (A): 162,660 (derivative) | EDGAR |
| 2022-11-21 | 4 | Hurvitz Chaim — Director | Purchase (P): 287,812 @ $0.99 · Purchase (P): 171,780 @ $1.08 · Purchase (P): 40,408 @ $1.10 · Grant/award (A): 162,660 (derivative) | EDGAR |
| 2022-11-18 | 4 | Javitt Daniel C. — 10% owner | Sale (S): 133,719 @ $1.02 · Sale (S): 33,018 @ $1.05 | EDGAR |
| 2022-11-15 | 4 | Javitt Daniel C. — 10% owner | Sale (S): 49,200 @ $1.01 | EDGAR |
| 2022-08-02 | 4 | Javitt Daniel C. — 10% owner | Sale (S): 784,063 @ $1.01 | EDGAR |
| 2022-07-05 | 4 | Javitt Daniel C. — 10% owner | Gift (G): 2,000,000 @ $0 | EDGAR |
| 2022-06-07 | 4 | Javitt Daniel C. — 10% owner | Sale (S): 243,596 @ $0.70 · Sale (S): 115,657 @ $0.67 · Sale (S): 86,459 @ $0.65 | EDGAR |
| 2022-06-02 | 4 | Javitt Jonathan C — Chief Scientist, Director, 10% owner | Purchase (P): 100,000 @ $58 | EDGAR |
| 2022-06-02 | 4/A | Javitt Jonathan C — Chief Scientist, Director, 10% owner | Purchase (P): 100,000 @ $0.58 | EDGAR |
| 2022-03-10 | 4 | Besthof Robert — Interim CEO | Grant/award (A): 100,000 (derivative) @ $2.61 | EDGAR |
| 2021-11-02 | 4 | McMaster Herbert Raymond — Director | Option exercise (M): 18,300 @ $2.22 · Conversion (C): 28,724 (derivative) @ $2.22 · Grant/award (A): 10,424 (derivative) @ $0 | EDGAR |
| 2021-11-02 | 4 | Javitt Daniel C. — 10% owner | Gift (G): 434,594 · Gift (G): 434,594 | EDGAR |
| 2021-11-02 | 4 | Daigneault Alessandra — General Counsel & Secretary | Option exercise (M): 27,395 @ $3.07 · Sale (S): 33,715 @ $13.11 · Option exercise (M): 18,420 @ $3.07 · Option exercise (M): 13,164 @ $3.07 · Conversion (C): 43,000 (derivative) @ $3.07 · Grant/award (A): 15,605 (derivative) @ $0 · +4 more | EDGAR |
| 2021-11-02 | 4 | Besthof Robert — Chief Comm. & Patient Officer | Option exercise (M): 63,710 @ $0.20 · Sale (S): 40,000 @ $11.76 · Conversion (C): 100,000 (derivative) @ $0.20 · Grant/award (A): 36,290 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | Javitt Daniel C. — 10% owner | Grant/award (A): 13,971,864 | EDGAR |
| 2021-06-10 | 4 | Gorovitz Aaron — Director | Grant/award (A): 8,336 · Grant/award (A): 8,336 · Grant/award (A): 8,336 · Grant/award (A): 16,678 | EDGAR |
| 2021-06-10 | 4 | Glied Sharon — Director | Grant/award (A): 13,168 · Grant/award (A): 65,437 (derivative) | EDGAR |
| 2021-06-10 | 4 | Fricker William — CFO & Treasurer | Grant/award (A): 99,200 (derivative) · Grant/award (A): 99,200 (derivative) | EDGAR |
| 2021-06-10 | 4 | Flynn Patrick John — Director | Grant/award (A): 362,332 · Grant/award (A): 35,209 · Grant/award (A): 35,209 · Grant/award (A): 692,639 (derivative) · Grant/award (A): 692,639 (derivative) | EDGAR |
| 2021-06-10 | 4 | Daigneault Alessandra — General Counsel & Secretary | Grant/award (A): 6,320 · Grant/award (A): 143,840 (derivative) · Grant/award (A): 49,600 (derivative) · Grant/award (A): 148,800 (derivative) | EDGAR |
| 2021-06-10 | 4 | Besthof Robert — Chief Comm. & Patient Officer | Grant/award (A): 347,200 (derivative) · Grant/award (A): 347,200 (derivative) | EDGAR |
| 2021-06-10 | 4 | Hurvitz Chaim — Director | Grant/award (A): 1,436,350 · Grant/award (A): 208,443 · Grant/award (A): 218,423 (derivative) | EDGAR |
| 2021-06-10 | 4 | Troy Daniel — Director | Grant/award (A): 43,093 · Grant/award (A): 65,437 (derivative) | EDGAR |
| 2021-06-10 | 4 | Javitt Jonathan C — Chief Executive Officer, Director, 10% owner | Grant/award (A): 46,332 · Grant/award (A): 13,348,997 · Grant/award (A): 1,422,000 | EDGAR |
Recent 8-K events — NRX Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-07-22 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NRXP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs